Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.
Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12(16.6%) and a partial response in 4/12 (33.3%). Two of 8 patients with a platelet count < 100 x 10(9)/L had a complete response, as did 3/9 with a neutrophil count < 1.5 x 10(9)/L. Compared to rHuEpo or amifostine used as single agents, their combination did not offer substantial advantages.
Grossi
Alberto
A
Musto
Pellegrino
P
Santini
Valeria
V
Balestri
Francesca
F
Fabbri
Alberto
A
Falcone
Antonietta
A
Sanpaolo
Grazia
G
D000368:Aged; D000369:Aged, 80 and over; D004999:Amifostine / Q000008:administration & dosage*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D011994:Recombinant Proteins; D016896:Treatment Outcome
D011994:Recombinant Proteins; D004921:Erythropoietin; D004999:Amifostine